Fiche société
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| TQB2825 Injection (Subcutaneous Injection)The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies. | SEP | Phase 1 | Immunomodulation | China | À vérifier |
| TQB2825 Injection (Subcutaneous Injection)The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies. | SEP | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| TQB2825 Injection (Subcutaneous Injection) | SEP | Phase 1 | NCT07110194 | Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||